GSK's Ware Ellipta plant to supply US after Zebulon line operational

By Gareth Macdonald

- Last updated on GMT

GSK in Ware, UK (image: Google maps)
GSK in Ware, UK (image: Google maps)

Related tags Dry powder inhalers Asthma

GSK has confirmed its new UK plant will continue to supply the US with Ellipta inhalers after capacity at its facility in North Carolina comes online this year.

GSK opened the £56m ($80m) plant -  named Building U3 - in Ware, Hertfordshire last week​ at a site adjacent to its existing Ellipta manufacturing facility. The firm said together the plants will produce 37m inhalers a year by 2017 and supply multiple international markets.

A spokeswoman told us “currently we supply over 70 markets from Ware, which is increasing monthly as more markets launch products from our Ellipta portfolio.”

GSK is installing a line for the dry powder inhalers at its facility in Zebulon, North Carolina in the US however the Ware facilities will continue to supply the US.

Zebulon will come online this year with Ware continuing to manufacture for launch markets across the world​" the spokeswoman said.

The Ellipta​ inhaler differs from GSK’s diskus system – which is used to deliver Advair – in that can hold one or two blister strips, with each blister containing a sealed single dose of medication.

This means it can be used to deliver drugs containing one or two APIs and – according to the authors of a GSK funded study – “enables the formulations for each product to be developed individually, since they are stored separately until the point of administration​.”

Ellipta is used to deliver a range of GSK’s respiratory drugs, including the combination asthma and chronic obstructive pulmonary disease (COPD) drug Relvar/Breo, a version of the product called Revinity that is sold in Italy and the COPD monotherapy Incruse.

The Ware plant supplies the Ellipta device for these and will “also make clinical trials supply for the inhaled products which are in development​” according to the spokeswoman.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us


View more